You have designed a clinical trial to evaluate a novel agent…
You have designed a clinical trial to evaluate a novel agent using a classic 3+3 clinical trial design. You start at dose level 1 and within the first 3 patients on this dose level, there are 2 dose limiting toxicities. What is the next step?
Read Details